查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1298391

肌萎缩侧索硬化症治疗市场：按药物、类型和分销渠道划分：2023-2032 年全球机会分析和行业预测

Amyotrophic Lateral Sclerosis Treatment Market By Drugs, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 260 Pages | 商品交期: 2-3个工作天内

价格

2022年肌萎缩侧索硬化症治疗市场价值为6.6225亿美元，预计2032年将达到10.3894亿美元，2023年至2032年復合年增长率为4.6%

Amyotrophic Lateral Sclerosis Treatment Market-IMG1

肌萎缩侧索硬化症 (ALS)，也称为卢伽雷氏病，是一种影响大脑和脊髓神经细胞的进行性神经退行性疾病。ALS 逐渐破坏并杀死这些神经细胞，导致肌肉失去控制并最终瘫痪。ALS 的症状通常始于手脚无力或僵硬，并逐渐扩散到身体的其他部位。其他症状包括说话、吞嚥、呼吸困难以及肌肉痉挛或痉挛。目前 ALS 尚无治愈方法，治疗主要集中在控制症状和改善生活质量。

常用来治疗肌萎缩性侧索硬化症的药物包括利鲁唑、依达拉奉、苯丁酸钠和牛磺迪奥。利鲁唑的作用是抑制谷氨酸的释放，谷氨酸是一种损害运动神经元的神经递质，而依达拉奉是一种自由基清除剂，可以减少体内损害运动神经元的氧化应激。

推动全球肌萎缩侧索硬化症治疗市场增长的主要因素包括肌萎缩侧索硬化症患病率的增加以及 ALS 新药和治疗方法的批准增加。随着世界人口老龄化，肌萎缩侧索硬化症的患病率预计将上升，从而导致对有助于控制症状和减缓疾病进展的治疗和药物的需求增加。我在这里。

另一个市场驱动因素是医疗保健专业人员、患者和护理人员对 ALS 的认识和理解不断增强。ALS 研究的进步和医疗技术的进步增加了我们对 ALS 潜在机制和潜在治疗靶点的了解。因此，基因疗法和干细胞疗法等开发正在取得进展，预计市场在预测期内将会增长。

目录

第 1 章 简介

第二章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态
    • 促进者
      • 提高对 ALS 的认识和理解
      • 肌萎缩侧索硬化症患病率增加
      • 政府和非政府组织的努力
    • 阻碍因素
      • 药物副作用
    • 机会
      • 增加研发活动
  • COVID-19 市场影响分析

4 肌萎缩侧索硬化症治疗市场（按代理商）

  • 概述
    • 市场规模和预测
  • 利鲁唑
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 依达拉奉
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

5 肌萎缩侧索硬化症治疗市场（按类型）

  • 概述
    • 市场规模和预测
  • 散发性肌萎缩侧索硬化症
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 家族性肌萎缩侧索硬化症
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

6 肌萎缩侧索硬化症治疗市场（按分销渠道）

  • 概述
    • 市场规模及预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 在线提供商
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 药店和零售药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

7 肌萎缩侧索硬化症治疗市场（按地区）

  • 概述
    • 市场规模/预测：按地区
  • 北美
    • 主要趋势和机遇
    • 市场规模/预测：按药物分类
    • 市场规模/预测：按类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
  • 欧洲
    • 主要趋势和机遇
    • 市场规模/预测：按药物分类
    • 市场规模/预测：按类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 欧洲其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
  • 亚太地区
    • 主要趋势和机遇
    • 市场规模/预测：按药物分类
    • 市场规模/预测：按类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 亚太其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
  • 拉丁美洲/中东/非洲
    • 主要趋势和机遇
    • 市场规模/预测：按药物分类
    • 市场规模/预测：按类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分
      • 其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按药物分类
      • 市场规模/预测：按类型
      • 市场规模和预测：按分销渠道划分

第8章 竞争格局

  • 介绍
  • 关键成功策略
  • 10大公司产品图
  • 比赛仪表板
  • 比赛热图
  • 2022 年顶级公司定位

第九章公司简介

  • Amylyx Pharmaceuticals, Inc.
  • Aquestive Therapeutics, Inc.
  • Covis Pharma GmbH
  • Glenmark Pharmaceuticals Limited
  • ITALFARMACO S.p.A.
  • Mitsubishi Chemical Group Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Alkem Laboratories Ltd
  • Otsuka Pharmaceutical Co., Ltd.
Product Code: A10244

The amyotrophic lateral sclerosis treatment market valued for $662.25 million in 2022 and is estimated to reach $1,038.94 million by 2032, exhibiting a CAGR of 4.6% from 2023 to 2032.

Amyotrophic Lateral Sclerosis Treatment Market - IMG1

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS causes these nerve cells to gradually break down and die, which results in the loss of muscle control and eventual paralysis. The symptoms of ALS typically begin with muscle weakness or stiffness, often in the hands or feet, and gradually spread to other parts of the body. Other symptoms include difficulty speaking, swallowing, or breathing, as well as muscle cramps and twitching. There is currently no cure for ALS, and treatment mainly focuses on managing symptoms and improving the quality of life for people with the disease.

Some of the drugs that are commonly used to treat amyotrophic lateral sclerosis include Riluzole, Edaravone, and Sodium phenylbutyrate and taurursodio. Riluzole works by reducing the release of glutamate, a neurotransmitter that damage motor neurons and Edaravone is a free radical scavenger that works by reducing oxidative stress in the body, which damage the motor neurons.

The major factors that drive the growth of the global amyotrophic lateral sclerosis treatment market include, increase in prevalence of amyotrophic lateral sclerosis, and rise in approval of new drugs and therapies for ALS. The incidence of ALS is expected to rise, as the global population ages, leading to a growth in demand for treatments and therapies that may help to manage the symptoms and slow the progression of the disease.

Another market driver is the growth in awareness and understanding of ALS among healthcare professionals, patients, and caregivers. There is a greater understanding of the underlying mechanisms of ALS and potential targets for treatment with more research being done on the disease and advances in medical technology. This has led to the development of new therapies, such as gene therapies and stem cell treatments, which are expected to drive market growth during the forecast period.

In addition, regulatory frameworks and reimbursement policies may also impact the market for ALS treatments. The approval of new drugs and therapies by regulatory bodies, such as the U.S. FDA, may drive market growth by providing patients with access to new and innovative treatments. For instance, increase in pipeline products such as Tofersen, ANX005 and others for treating an amyotrophic lateral sclerosis which is anticipated to provide lucrative opportunities to the market players. Reimbursement policies that provide coverage for these treatments can also help to expand the market by making them more accessible and affordable for patients.

However, limited understanding of the disease, stringent regulatory process for approving new treatments for ALS, which can delay the availability of new therapies for patients and higher treatment may restrict the market growth.

The amyotrophic lateral sclerosis treatment market is segmented into drug, type, distribution channel, and region. On the basis of drug, the market is categorized into Riluzole, Edaravone, and others. On the basis of type, the market is bifurcated into sporadic ALS and familial ALS. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global amyotrophic lateral sclerosis treatment market are: Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltd. Key players operating in the market have adopted product approval, agreement, and product launch as their key strategies to expand their product portfolio. For instance, in January 2023, Amylyx Pharmaceuticals, Inc. announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm is expected to commercialize to regulatory review and approval of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the amyotrophic lateral sclerosis treatment market analysis from 2022 to 2032 to identify the prevailing amyotrophic lateral sclerosis treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the amyotrophic lateral sclerosis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global amyotrophic lateral sclerosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drugs

  • Riluzole
  • Edaravone
  • Others

By Type

  • Sporadic ALS
  • Familial ALS

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Alkem Laboratories Ltd
    • Amylyx Pharmaceuticals, Inc.
    • Aquestive Therapeutics, Inc.
    • Covis Pharma GmbH
    • Glenmark Pharmaceuticals Limited
    • ITALFARMACO S.p.A.
    • Mitsubishi Chemical Group Corporation
    • Otsuka Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growth in awareness and understanding of ALS
      • 3.4.1.2. Increase in prevalence of amyotrophic lateral sclerosis
      • 3.4.1.3. Initiatives by government and non-government organizations
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects of drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Riluzole
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Edaravone
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Sporadic ALS
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Familial ALS
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drugs
    • 7.2.3. Market size and forecast, by Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drugs
      • 7.2.5.1.3. Market size and forecast, by Type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drugs
      • 7.2.5.2.3. Market size and forecast, by Type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drugs
      • 7.2.5.3.3. Market size and forecast, by Type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drugs
    • 7.3.3. Market size and forecast, by Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drugs
      • 7.3.5.1.3. Market size and forecast, by Type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drugs
      • 7.3.5.2.3. Market size and forecast, by Type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drugs
      • 7.3.5.3.3. Market size and forecast, by Type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drugs
      • 7.3.5.4.3. Market size and forecast, by Type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drugs
      • 7.3.5.5.3. Market size and forecast, by Type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drugs
      • 7.3.5.6.3. Market size and forecast, by Type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drugs
    • 7.4.3. Market size and forecast, by Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drugs
      • 7.4.5.1.3. Market size and forecast, by Type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drugs
      • 7.4.5.2.3. Market size and forecast, by Type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drugs
      • 7.4.5.3.3. Market size and forecast, by Type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drugs
      • 7.4.5.4.3. Market size and forecast, by Type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drugs
      • 7.4.5.5.3. Market size and forecast, by Type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drugs
      • 7.4.5.6.3. Market size and forecast, by Type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drugs
    • 7.5.3. Market size and forecast, by Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drugs
      • 7.5.5.1.3. Market size and forecast, by Type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drugs
      • 7.5.5.2.3. Market size and forecast, by Type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drugs
      • 7.5.5.3.3. Market size and forecast, by Type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drugs
      • 7.5.5.4.3. Market size and forecast, by Type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Amylyx Pharmaceuticals, Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Aquestive Therapeutics, Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Covis Pharma GmbH
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. Glenmark Pharmaceuticals Limited
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. ITALFARMACO S.p.A.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Mitsubishi Chemical Group Corporation
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Viatris Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Alkem Laboratories Ltd
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Otsuka Pharmaceutical Co., Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 02. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR RILUZOLE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR EDARAVONE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 06. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR SPORADIC ALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR FAMILIAL ALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 18. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 21. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 37. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 40. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 56. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 59. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 62. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. AMYLYX PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 87. AMYLYX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 88. AMYLYX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 89. AMYLYX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 90. AMYLYX PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 91. AQUESTIVE THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 92. AQUESTIVE THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 93. AQUESTIVE THERAPEUTICS, INC.: PRODUCT SEGMENTS
  • TABLE 94. AQUESTIVE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 95. COVIS PHARMA GMBH: KEY EXECUTIVES
  • TABLE 96. COVIS PHARMA GMBH: COMPANY SNAPSHOT
  • TABLE 97. COVIS PHARMA GMBH: PRODUCT SEGMENTS
  • TABLE 98. COVIS PHARMA GMBH: PRODUCT PORTFOLIO
  • TABLE 99. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 100. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 101. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 102. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 103. ITALFARMACO S.P.A.: KEY EXECUTIVES
  • TABLE 104. ITALFARMACO S.P.A.: COMPANY SNAPSHOT
  • TABLE 105. ITALFARMACO S.P.A.: PRODUCT SEGMENTS
  • TABLE 106. ITALFARMACO S.P.A.: PRODUCT PORTFOLIO
  • TABLE 107. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY EXECUTIVES
  • TABLE 108. MITSUBISHI CHEMICAL GROUP CORPORATION: COMPANY SNAPSHOT
  • TABLE 109. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT SEGMENTS
  • TABLE 110. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT PORTFOLIO
  • TABLE 111. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY STRATERGIES
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 116. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 120. ALKEM LABORATORIES LTD: KEY EXECUTIVES
  • TABLE 121. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 122. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
  • TABLE 123. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 124. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 125. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 126. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 127. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALAMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET
  • FIGURE 10. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR RILUZOLE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR EDARAVONE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR SPORADIC ALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR FAMILIAL ALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET BY REGION, 2022
  • FIGURE 22. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. AMYLYX PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. AQUESTIVE THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AQUESTIVE THERAPEUTICS, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. MITSUBISHI CHEMICAL GROUP CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. MITSUBISHI CHEMICAL GROUP CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)